Company: ARTL
Filing Date: 2025-12-11
Form Type: DEF 14A
Source: 0001640334-25-002308
Chunk: 19

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-12-11
Form: DEF 14A
Chunk 19
---
. |
| · | The Chief Executive Officer and the Chair of the Board jointly establish the agenda for each meeting of the Board, though any director may request the inclusion of items on the agenda.                                                                                                                                                                                                                                                                                                                                                                  |

Ms. Matsui currently serves as Chair of the Board and is an independent director, thus, the Board does not currently have a lead independent director. The Board has determined that this leadership structure, specifically the separation of the Chief Executive Officer and Chair of the Board positions, is appropriate for our company because, in the judgment of the Board, an independent Chair of the Board (or lead independent director, if the Chair of the Board is not an independent director) is best positioned to express to management the views of the Board (and, particularly, the independent directors) and to provide constructive feedback to the Chief Executive Officer regarding management’s performance.

Board Committees

The Board has an Audit Committee, a Compensation Committee, and a Corporate Governance and Nominating Committee. Each of these committees operate under written charters, each of which are available on our website at http://www.artelobio.com under “Investors—Governance.” The Board has determined that all members of these committees satisfy the applicable independence requirements under Nasdaq rules. The current members of the committees are identified in the table below.

| Director                      |     | Audit Committee |        |     | Compensation Committee |        |     | Corporate Governance and Nominating Committee |        |
| Gregory D. Gorgas             |     |                 | —      |     |                        | —      |     |                                               | —      |
| Connie Matsui                 |     |                 | Member |     |                        | —      |     |                                               | Member |
| Steven Kelly                  |     |                 | Member |     |                        | Chair  |     |                                               | —      |
| R. M. Emanuele, Ph.D.         |     |                 | —      |     |                        | —      |     |                                               | Member |
| Douglas Blayney, M.D.         |     |                 | —      |     |                        | —      |     |                                               | Chair  |
| Gregory R. Reyes, M.D., Ph.D. |     |                 | —      |     |                        | Member |     |                                               | —      |
| Tamara A. Favorito            |     |                 | Chair  |     |                        | Member |     |                                               | —      |

| 10 |

The Audit Committee is responsible primarily